Latest News
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment
17 March 2026 - US biopharmaceutical company Sentynl Therapeutics Inc, a wholly-owned subsidiary of Zydus Lifesciences Limited, announced on Monday that it has signed an agreement with PRG S&T, a Korea-based developer of medicine for rare genetic...
ONL Therapeutics reports start of European Phase 2 trial of xelafaslatide for GA associated with dry AMD
17 March 2026 - ONL Therapeutics Inc, a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced on Monday that the first European participant has been randomised in the...
Laronix and Greater Baltimore Medical Center launch Laronix MIRA Voice investigational study
17 March 2026 - Laronix Inc, a commercial-stage medical technology company involved in voice restoration technologies, and the Greater Baltimore Medical Center (GBMC) announced on Monday the launch of an investigational study of Laronix MIRA Voice to...
NeuroSense Therapeutics reports Phase 2b trial results of PrimeC in ALS
17 March 2026 - Late-stage clinical biotechnology company NeuroSense Therapeutics Ltd (NASDAQ:NRSN) announced on Monday that results from the Phase 2b clinical trial (PARADIGM) of PrimeC in people living with amyotrophic lateral sclerosis (ALS) have ...
Convatec launches co-branded eakin freeseal ostomy seal in North America
16 March 2026 - Medical products and technologies company Convatec (LSE:CTEC) and Eakin Healthcare, a specialist in ostomy solutions, on Monday announced the launch of the co-branded eakin freeseal in the US, expanding Convatec's ESENTA accessor...